**Medication for Substance Use Disorder**

**AMERSA Conference 2023**

1. Telehealth only buprenorphine programs: what are different models, insurance coverage, use of peers or other case management support.  It would be helpful to better understand the changing landscape of requirements for telehealth and controlled substance prescribing by state.  What are the concerns around diversion?
2. Injectable buprenorphine products: challenges in inpatient implementation and getting it on formulary at the hospital, discussed brixadi and potential implications for use instead of microinducations
3. Low dose cross taper for buprenorphine induction: discussion of patient selection, challenges